New biologic LP-003 takes first step in human safety trial

NCT ID NCT06294288

Completed Knowledge-focused Sponsor: Longbio Pharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety and tolerability of a new biologic drug called LP-003 in 60 healthy volunteers. The drug is being developed for chronic spontaneous urticaria (long-lasting hives). The trial gave single or multiple doses of LP-003 or a placebo by IV to see how the body handles it and to check for side effects. As a Phase 1 first-in-human study, it is an early step to find a safe dose before testing in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-003 (a biologic drug given intravenously)
What this could lead to: If this early safety study succeeds, it could pave the way for a new treatment option for chronic spontaneous urticaria (long-lasting hives).
What could go wrong: This is a very early Phase 1 trial in only 60 healthy people, not patients. It is designed to check safety and dosing, not to prove the drug works. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.